This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Cicek, M. Articles by Oursler, M. J. Search for Related Content PubMed PubMed Citation Articles by Cicek, M. Articles by Oursler, M. J.

2-Methoxyestradiol Suppresses Osteolytic Breast Cancer Tumor Progression In vivo

¹ Endocrine Research Unit, Mayo Clinic College of Medicine, Rochester, Minnesota; ² College of Health and Human Sciences, Oregon State University, Corvallis, Oregon; and ³ Department of Orthopedic Surgery, University of Minnesota, Minneapolis, Minnesota

Requests for reprints: Muzaffer Cicek, Endocrine Research Unit, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN 55905. Phone: 507-255-1486; Fax: 507-255-4828; E-mail: Muzaffer.Cicek{at}Mayo.edu.

2-Methoxyestradiol (2ME₂), a physiologic metabolite of 17ß-estradiol (estrogen), has emerged as a promising cancer therapy because of its potent growth-inhibitory and proapoptotic effects on both endothelial and tumor cells. 2ME₂ also suppresses osteoclast differentiation and induces apoptosis of mature osteoclasts, and has been shown to effectively repress bone loss in an animal model of postmenopausal osteoporosis. Given these observations, we have examined whether 2ME₂ could effectively target metastasis to bone, osteolytic tumors, and soft tissue tumors. A 4T1 murine metastatic breast cancer cell line was generated that stably expressed Far Red fluorescence protein (4T1/Red) to visualize tumor development and metastasis to bone. In an intervention study, 4T1/Red cells were injected into bone marrow of the left femur and the mammary pad. In the latter study, 2ME₂ (10, 25, and 50 mg/kg/d) treatment began on the same day as surgery and was continued for the 16-day duration of study. Tumor cell growth and metastasis to bone were monitored and bone volume was determined by micro-computed tomography. 2ME₂ inhibited tumor growth in soft tissue, metastasis to bone, osteolysis, and tumor growth in bone, with maximum effects at 50 mg/kg/d. Furthermore, tumor-induced osteolysis was significantly reduced in mice receiving 2ME₂. In vitro, 2ME₂ repressed osteoclast number by inducing apoptosis of osteoclast precursors as well as mature osteoclasts. Our data support the conclusion that 2ME₂ could be an important new therapy in the arsenal to fight metastatic breast cancer. [Cancer Res 2007;67(21):10106–11]